arrow
M

Michael Maschan

Russian Academy of Sciences
H指数:28
被引数:2,982

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

An Endemic Region of Thiamine-Responsive Megaloblastic Anemia Caused by an SLC19A2 c.1223+1G>A Founder Mutation

由SLC19A2 c.1223+1G>A奠基者突变引起的硫胺素反应性巨幼细胞性贫血的特有区域

2026-08-120
OA
Diagnostic workflow for X-linked agammaglobulinemia integrating BTK expression and B-cell maturation analysis by flow cytometry

通过流式细胞术整合BTK表达和B细胞成熟分析的诊断流程:X连锁无丙种球蛋白血症

2026-01-010
PRE
Long-term outcomes of αβ T-cell/CD19 B-cell-depleted peripheral blood stem cell transplantation from unrelated donors in pediatric and adolescent patients with severe aplastic anemia: a single-center study

来自无关供者的αβ T细胞/CD19 B细胞耗竭的外周血干细胞移植治疗儿童和青少年重症再生障碍性贫血患者的长期结局:一项单中心研究

2025-08-220
PRE
Very early recovery of T cells after alpha/beta T cell-depleted haploidentical HSCT predicts the outcome in children with leukemia

α/β T细胞去除的半合子造血干细胞移植后T细胞的极早期恢复预测白血病患儿的结局

2025-08-050
PRE
Post-transplant cyclophosphamide, abatacept, and vedolizumab to prevent GVHD after hematopoietic stem cells transplantation in children with acute leukemia: results of a prospective trial

移植后环磷酰胺、阿巴西特和 vedolizumab 预防儿童急性白血病患者造血干细胞移植后 GVHD 的效果:一项前瞻性试验的结果

2025-04-250
PRE
Extended characterization of anti-CD19 CAR T cell products manufactured at the point of care using the CliniMACS Prodigy system: comparison of donor sources and process duration

使用CliniMACS Prodigy系统在护理点生产的anti-CD19 CAR T细胞产品的扩展表征: 供体来源和过程持续时间的比较

2024-06-010
PRE
Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E-positive LCH
2023-09-1310
OAAI
Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2
2022-05-0913
OA